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OBJECTIVE—An association between insulin resistance and microalbuminuria in type 2 di-
abeteshasoftenbeenfoundincross-sectionalstudies. We aimedto reassess this relationshipina
prospective Taiwanese cohort of type 2 diabetic subjects.
RESEARCH DESIGN AND METHODS—We enrolled 738 normoalbuminuric type 2
diabeticsubjects,aged56.669.0years,between2003and2005andfollowedthemthroughthe
end of 2009. Average follow-up time was 5.2 6 0.8 years. We used urine albumin-to-creatinine
ratio to deﬁne microalbuminuria and the homeostasis model assessment of insulin resistance
(HOMA-IR) to assess insulin resistance. The incidence rate ratio and Cox proportional hazards
model were used to evaluate the association between HOMA-IR and development of micro-
albuminuria.
RESULTS—Wefoundincidencesofmicroalbuminuriaof64.8,83.5,93.3,and99.0per1,000
person-years for the lowest to highestquartilesof HOMA-IR. Compared with those in thelowest
quartile of HOMA-IR, the incidence rate ratios for those in the 2nd, 3rd, and highest quartiles
were 1.28 (95% CI 0.88–1.87), 1.44 (0.99–2.08), and 1.52 (1.06–2.20), respectively (trend
test:P,0.001).Bycomparisonwiththoseinthelowestquartile,theadjustedhazardratioswere
1.37 (0.93–2.02), 1.66 (1.12–2.47), and 1.76 (1.20–2.59) for those in the 2nd, 3rd, and highest
HOMA-IR quartiles, respectively.
CONCLUSIONS—According to the dose-response effects of HOMA-IR shown in this pro-
spective study, we conclude that insulin resistance could signiﬁcantly predict development of
microalbuminuria in type 2 diabetic patients.
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M
icroalbuminuria has long been
recognized as an important bio-
marker to predict micro- and
macrovascular complications and mortal-
ity for patients with type 2 diabetes (1).
Of many established risk factors linked
to the development of microalbumin-
uria, insulin resistance—one of the fun-
damental pathogenic features of type 2
diabetes—deservesourspecialattention.
The signiﬁcant association between insu-
lin resistance and microalbuminuria in
type 2 diabetes has frequently been dem-
onstrated across different ethnic popula-
tions.InHongKong,Chanetal.(2)found
that diabetic patients with albuminuria
had a higher homeostasis model assess-
ment (HOMA) score than those without
albuminuria. In Japan, a case-control
study identiﬁed the HOMA score as an
independent variable for urinary albumin
excretion in diabetic patients (3). In Italy,
Parvanova et al. (4) showed a signiﬁcant
association between glucose disposal rate
and microalbuminuria, and De Cosmo
et al. (5) revealed that diabetic males in
the highest quartile of the HOMA were
more likely than those in the lowest to
be associated with microalbuminuria. In
Iran (6), diabetic patients in the highest
quartile of HOMA were also found more
likely to have increased urinary albumin
excretion. However, to our best knowl-
edge,researchdesignatedtodepictthere-
lationship between insulin resistance and
microalbuminuria has been conducted
primarily with a cross-sectional design.
None of the aforementioned results have
been reconﬁrmed by a prospective cohort
research.Thepurposeofthisstudywasto
explore the effects of insulin resistance on
microalbuminuria development in a pro-
spective Taiwanese cohort of type 2 dia-
betic subjects.
RESEARCH DESIGN AND
METHODS—The study subjects were
type 2 diabetic patients enrolled in the
diabetes management through an inte-
grated delivery system (DMIDS) project
(NCT00288678, ClinicalTrials.gov) (6).
The patient recruitment period was be-
tween August 2003 and December 2005,
with the project carried out through
December 2009. All type 2 diabetic sub-
jects were eligible to be recruited unless
they met any of the following exclusion
criteria: 1) those aged ,30 or .70 years;
2) type 1 diabetic patients; 3)p r e g n a n t
women; and 4)t h o s ew h oh a dm a j o r
diabetes complications including leg
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ORIGINAL ARTICLEamputation, uremia, or hospitalization in
the previous year as the result of acute
myocardial infarction, heart failure, or
stroke. The number of original enrollees
having at least two interpretable labora-
tory tests was 1,209. Of these enrollees,
22 subjects receiving insulin injection,
323withaurinealbumin-to-creatininera-
tio (ACR) $30 mg/g in at least one of the
ﬁrst two urinetests, and 126subjectswith
missing fasting insulin data at baseline
were excluded. The remaining 738 sub-
jects, who had normoalbuminuria (ACR
,30 mg/g in the ﬁrst two consecutive
urine tests), were selected for further in-
vestigation.Writteninformedconsentwas
obtained from all enrollees. The institu-
tional review board at the National Health
Research Institutes reviewed and ap-
proved this study.
Laboratory tests
Fasting (overnight for at least 8 h) venous
blood and spot urine specimens were
collected every 6 months. Glycated he-
moglobin(HbA1c)wasmeasuredbyhigh-
performance liquid chromatography
(Variant II; Bio-Rad Laboratories, Hercu-
les, CA). Fasting glucose, triglycerides,
and HDL cholesterol were measured by
an automatic analyzer (Hitachi 7060;
Hitachi High Technologies,Tokyo, Japan).
Insulin was measured by a chemilumines-
cent immunometric assay (Immulite 1000;
Diagnostic Products, Los Angeles, CA).
Urinary albumin was measured by the im-
munoturbidimetricmethod(Hitachi7060;
Hitachi High Technologies,Tokyo, Japan).
Dipstick urinalysis was performed by an
automated chemical analyzer (Clinitek
500; Bayer, Elkhart, IN). All blood and
urine samples were kept in temperature-
proofcontainersat2°Cto8°C,transported
by express delivery to a central laboratory,
and measured within 8 h.
Variable deﬁnition and
anthropometric measurement
Waist circumference was measured at the
level of the midpoint between the lowest
rib and the iliac crest. A mercury sphyg-
momanometer was used to measure
blood pressure after subjects sat for 5 min.
Systolic blood pressure was recorded as
the ﬁrst perception of successive sounds.
Diastolic blood pressure was marked at
the complete disappearance of sound.
Blood pressure was measured three times
separated by 1 min; the mean of these
three measurements was recorded. We
used the HOMA of insulin resistance
(HOMA-IR) to assess insulin resistance
(HOMA-IR = {insulin [mU/L] 3 fasting
glucose [mmol/L]}/22.5) (7).
The primary end point of this study
was development of microalbuminuria.
Those who had ACR $30 mg/g in two
consecutive urine tests were deﬁned as
havingmicroalbuminuria.Theurinesam-
pleswereexcludedfromanalysisifmicro-
scopic urinalysis showed erythrocytes
.5/high-power ﬁeld (HPF), white blood
cells .5/HPF, epithelial cells .5/HPF,
and appearance of casts or bacteria.
Those who had smoked fewer than
100 cigarettes in their lifetime were de-
ﬁned as nonsmokers. For those who had
smoked .100 cigarettes, ex-smokers
were deﬁned as having stopped smoking
completely at least 1 month prior to re-
cruitment and current smokers as having
a daily or occasional smoking habit at the
time of recruitment.
Statistical analysis
Data were expressed as mean 6 SD for
continuous variables, or as counts and
proportions for categorical variables.
Student t tests and x
2 analyses were used
for continuous and categorical variables,
respectively. The incidence rate of micro-
albuminuria in the follow-up period was
estimated by the number of observed new
microalbuminuriacasesper1,000person-
years. The person-years were calculated
as the time elapsed from the date of re-
cruitment until the date of death, micro-
albuminuria development, or the end of
follow-up, whichever came ﬁrst. The cal-
culation of a 95% CI for the incidence
rate was based on the assumption that
the observed incident cases followed a
Poisson distribution. We estimated the
incidence rate of microalbuminuria in dif-
ferent HOMA-IR quartiles not only for
Table 1—Baseline demographic and biochemical characteristics of type 2 diabetic
patients with and without progression to microalbuminuria
Overall Normoalbuminuria Microalbuminuria P value
n 738 491 247
Male, n (%) 337 (45.6) 228 (46.4) 109 (44.3) 0.116
Education (#6 years), n (%) 376 (50.9) 230 (46.8) 146 (59.1) 0.034
Age at diabetes onset (years) 53.6 6 8.6 53.7 6 8.1 53.4 6 8.7 0.697
Diabetes duration at
recruitment (years) 2.9 6 2.6 2.9 6 2.7 3.0 6 3.0 0.453
Smoking status, n (%) 0.095
Nonsmoker 545 (73.8) 365 (74.3) 180 (72.9)
Ex-smoker 53 (7.2) 41 (8.4) 12 (4.5)
Current smoker 140 (19.0) 85 (17.3) 55 (22.6)
BMI (kg/m
2) 25.1 6 3.6 25.0 6 3.8 25.0 6 3.9 0.871
Waist circumference (cm) 86.6 6 10.4 88.5 6 11.1 86.5 6 10.3 0.076
HOMA-IR 3.7 6 3.1 3.5 6 3.2 4.0 6 3.2 0.026
Urine ACR (mg/g) 8.9 6 8.0 7.4 6 7.0 12.7 6 8.2 ,0.001
Triglycerides (mg/dL) 198.8 6 239.0 187.5 6 145.7 192.1 6 130.2 0.623
HDL cholesterol (mg/dL) 47.3 6 13.2 48.4 6 13.3 49.4 6 12.9 0.327
HbA1c (%) 8.15 6 1.86 8.01 6 1.82 8.42 6 1.94 0.010
Hypertension, n (%) 407 (58.3) 254 (51.7) 153 (61.9) 0.141
sBP (mmHg) 128.7 6 15.8 127 6 15.0 130 6 17.3 0.094
dBP (mmHg) 80.0 6 9.7 79.5 6 9.3 80.9 6 10.3 0.083
Medication use at baseline, n (%)
Statins 19 15 (3.0) 4 (1.4) 0.188
Sulfonylurea 627 406 (82.6) 221 (89.4) 0.878
Biguanide 572 369 (75.1) 203 (82.1) 0.863
Thiazolidinedione 78 51 (10.3) 27 (10.9) 0.923
a-Glucosidase inhibitor 36 25 (5.0) 11 (4.4) 0.853
Meglitinide 16 11 (2.2) 5 (2.0) 0.896
ACEI/ARB 245 155 (31.5) 90 (36.4) 0.485
CCB 196 126 (25.6) 70 (28.3) 0.426
b-Blocker 142 88 (17.9) 54 (21.8) 0.708
Diuretic 85 55 (11.2) 30 (12.1) 0.473
Data are n (%) or mean 6 SD unless otherwise indicated. sBP, systolic blood pressure; dBP, diastolic blood
pressure; CCB, calcium channel blocker.
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subgroups according to their glycemic
control (HbA1c #8 vs. .8%) and blood
pressure control (#130/80 vs. .130/80
mmHg).
Kaplan-Meier analyses and univariate
Cox proportional hazards models were
used to explore the association between
HOMA-IR and microalbuminuria devel-
opment. The predictors used in Cox pro-
portional hazards models—including
baseline demographic and metabolic pro-
ﬁles(ageatdiabetesonset,sex,education,
diabetes duration, smoking status, BMI,
waist circumference, triglycerides and
HDL cholesterol, urine ACR, HbA1c,a n d
hypertension status). Multivariable Cox
proportional hazards modeling was used
to determine the independent effects of
HOMA-IRonmicroalbuminuriadevelop-
ment. Covariates that were signiﬁcant at
the0.25levelwereenteredintoastepwise
model. Study entry was deﬁned as the
date of enrollment. Observations were
censored at the end of the study or the
date that patients died or dropped out of
the study, whichever occurred ﬁrst. Re-
sults were expressed as hazard ratios
( H R s )a n d9 5 %C I sc o m p a r e dw i t ht h e
reference group. To eliminate residual
confounding effects, for the survival anal-
ysis we also selected subjects who had
good metabolic proﬁles. They were those
whometthefollowingcriteriaatbaseline:
no ACEI (angiotensin-converting enzyme
inhibitor) and ARB (angiotensin II recep-
tor blocker) use, BMI ,24 kg/m
2, triglyc-
erides ,150 mg/dL, waist circumference
,80cm(female)or,90 cm (male),HDL
cholesterol .40 mg/dL (male) or .50
mg/dL (female), and blood pressure
,130/80 mmHg.
The proportional hazards assumption,
the constant HR over time, was evaluated
by comparing estimated log-log survival
curves for all covariates. All assessed log-
log survival plots graphically showed two
parallellines,indicatingnoviolationofthe
assumption.Atestfortrendwasconducted
by treating quartiles of HOMA-IR as a
continuous variable.
Analyses were performed with SAS
software,version9.1(SASInstitute,Cary,
NC).Atwo-sidedPvalue,0.05wascon-
sidered statistically signiﬁcant.
RESULTS—Table 1 displays demo-
graphic and biochemical characteristics
of study subjects. Compared with those
who retained a status of normoalbumin-
uria, patients who developed microalbu-
minuria were more likely to have lower
education, higher HOMA-IR, and higher
baseline ACR.
The Kaplan-Meier survival curves in
Fig. 1 indicate that the probability of re-
maining normoalbuminuric for those in
the 2nd to 4th HOMA-IR quartiles was
signiﬁcantly lower than for subjects in
the lowest quartile. The signiﬁcant ad-
justed HRs for those in 3rd and 4th quar-
tiles in the multivariable Cox proportional
hazards model, shown in Table 2, conﬁrm
the independent association between insu-
lin resistance and microalbuminuria devel-
opment. Figure 2 shows the adjusted HR
and trend test for those with good meta-
bolic proﬁles were similar to what was ob-
served for overall subjects.
Table 3 shows that the incidence of
microalbuminuria generally increased
with HOMA-IR. In addition to overall
Figure 1—Kaplan-Meier estimates of probability of normoalbuminuria according to 4 quartiles
of HOMA-IR at baseline.
Table 2—Cox proportional hazards models for progression to microalbuminuria*
Univariate
HR P value
Multivariable
HR† P value
Sex (male/female) 0.80 (0.62–1.03) 0.090 0.96 (0.69–1.34) 0.826
Education (#6 years/.6 years) 1.32 (1.02–1.70) 0.031 1.36 (1.00–1.83) 0.045
Age at diabetes onset (years) 1.01 (1.00–1.02) 0.048 0.99 (0.97–1.01) 0.448
Diabetes duration at recruitment
(years) 1.02 (1.01–1.03) 0.033 1.01 (0.96–1.06) 0.591
Smoking status
Ex-smoker/nonsmoker 0.52 (0.29–0.94) 0.030 0.56 (0.30–1.05) 0.073
Current smoker/nonsmoker 1.11 (0.82–1.50) 0.482 1.09 (0.76–1.56) 0.634
BMI (kg/m
2)1 . 0 0 ( 0 . 9 6 –1.03) 0.966 ——
Waist circumference (cm) 0.99 (0.98–1.00) 0.246 0.98 (0.97–1.00) 0.070
Urine ACR (mg/g) 1.06 (1.04–1.07) ,0.001 1.06 (1.04–1.06) ,0.001
Triglycerides (mg/dL) 1.00 (0.99–1.00) 0.417 ——
HDL cholesterol (mg/dL) 1.00 (0.99–1.04) 0.334 ——
Hypertension (yes/no) 1.27 (0.98–1.65) 0.064 1.39 (1.05–1.83) 0.020
HbA1c (%) 1.57 (1.30–1.89) ,0.001 1.26 (1.09–1.43) 0.026
HOMA-IR
Quartile 2/Quartile 1 1.41 (0.97–2.06) 0.068 1.37 (0.93–2.02) 0.110
Quartile 3/Quartile 1 1.68 (1.16–2.44) 0.005 1.66 (1.12–2.47) 0.011
Quartile 4/Quartile 1 1.73 (1.21–2.47) 0.002 1.76 (1.20–2.59) 0.003
DataareHR(95%CI).*ThecovariatesusedinCoxproportionalhazardsmodelswerebaselinedemographics
and biomedical markers. †The multivariate HRs were derived from a stepwise proportional hazards re-
gression model.
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remained true for type 2 diabetic patients
with poor glycemic or blood pressure
control. Furthermore, we classiﬁed the
HOMA-IR score based on its tertile in-
stead of quartile. The incidence rate ratios
of tertile 3, in comparison with tertile 1,
were 1.60 (95% CI 1.00–2.55), 2.71
(1.80–4.15), 1.92 (1.16–3.27), and 1.70
(1.14–2.54) for subgroups with HbA1c
#8%, HbA1c .8%, blood pressure
#130/80 mmHg and blood pressure
.130/80 mmHg, respectively. Their
P values (0.041, 0.022, 0.013, and 0.007,
respectively) for dose-response trend tests
were also signiﬁcant (data not shown).
CONCLUSIONS—Insulin resistance
is shown in this longitudinal study to
be a strong predictor in determining the
development of microalbuminuriawithin
5 years for the type 2 diabetic patients
with ACR ,30 mg/g at enrollment. Com-
pared with those with a HOMA-IR score
in the lowest quartile, those in the highest
quartile had increased incidences of
microalbuminuria by about 17% (for
those with poor blood pressure control)
to 92% (for those with good blood pres-
sure control). Furthermore, the adjusted
dose-response effect of insulin resistance
on development of microalbuminuria
was signiﬁcant in overall subjects and
the subgroup with good metabolic pro-
ﬁles. Overall, this prospective study pro-
vides new epidemiological evidence
linking elevated risk of diabetic nephrop-
athy with insulin resistance.
A growing body of studies has dem-
onstrated that insulin resistance is asso-
ciated with hemodynamic alteration in
the kidney. Hyperinsulinemia has been
reported to be able to raise glomerular
hydrostatic pressure, increase renal vas-
cular permeability, aggravate glomerular
hyperﬁltration, and enhance renal so-
dium reabsorption (8–10). Altogether,
the steady state of renal endothelial func-
tions and hemodynamic harmonization
may be changed because of cascading re-
actions caused by insulin resistance. This
couldexplain underlying mechanismsfor
the signiﬁcant association between the
HOMA-IR score and microalbuminuria
development observed in this study.
Similar to previous studies (3,11,12),
our study found that those with a higher
HOMA-IR were more likely to have met-
abolic syndrome (data not shown) and
higher urine ACR at baseline. Metabolic
syndrome and urine ACR have been well
recognized as risk factors associated with
microalbuminuria (2,4,5,13–15). Be-
cause of this intertwining feature in the
cluster of insulin resistance, metabolic
syndrome, and microalbuminuria, we
could not completely exclude the possi-
bility that insulin resistance is a biochem-
ical marker rather than a causal factor in
theprocessofmicroalbuminuriadevelop-
ment. In order to ensure the effects of
insulin resistance, we calculated the in-
cidence rate ratio and performed multi-
variable survival analyses for subjects
stratiﬁed by different baseline character-
istics.Thecausalassociationisconsidered
to be truly independent because the sig-
niﬁcantdose-responseeffectofHOMA-IR
on microalbuminuria development was
demonstrated (Fig. 2) not only in overall
subjects but also in type 2 diabetic sub-
jects with no ACEI/ARB use and good
metabolic proﬁles.
The inverse association between ed-
ucational attainment and microalbumin-
uria development is another noteworthy
ﬁnding. We found that the less educated
were also more likely to have higher
HbA1c and to be current smokers (data
not shown), both of which are risk factors
for the development of microalbumin-
uria. These ﬁndings are in accordance
with previous studies in both Western
andorientalcountries(16,17).Thisuniver-
sal evidence implies that those with lower
educational attainment are at higher risk of
developing chronic kidney disease.
Study ﬁndings may have to be inter-
preted cautiously for the following rea-
sons. First, we used the HOMA-IR index
instead of the hyperinsulinemic euglyce-
mic glucose clamp (18) to measure insu-
lin resistance. Although some previous
papers argued that the HOMA-IR index
might have limitations to assess insulin
resistance in certain circumstances (19),
it is the most frequently used index to
evaluate insulin resistance in the general
population and diabetic patients (20).
The UK Prospective Diabetes Study also
used the HOMA-IR index to monitor
insulin sensitivity in its type 2 diabetic
cohort (21). In line with other epidemio-
logic studies, we believe the classiﬁcation
Figure 2—Adjusted HR of microalbuminuria development in type 2 diabetic patients for overall
subjects and those with good metabolic proﬁles at baseline. Type 2 diabetic patients with good
metabolic proﬁles were those who had no ACEI/ARB use, BMI ,24 kg/m
2, triglycerides ,150
mg/dL, waist circumference ,80 cm (female) or ,90 cm (male), HDL cholesterol .40 mg/dL
(male)or.50mg/dL(female),andbloodpressure,130/80mmHg.Thecontrolledcovariatesin
the survival analyses included demographics (baseline age, sex, education, smoking status, and
diabetes duration) and baseline biomedical proﬁles (waist circumference, BMI, triglycerides,
ACR, HDL cholesterol, HbA1c, and mean arterial pressure). The reference group for each model
was those who were in the lowest quartile of the corresponding HOMA-IR index. The mean ar-
terial pressure (MAP) was calculated by the formula: mean arterial pressure = diastolic blood
pressure + 1/3 (systolic blood pressure – diastolic blood pressure). T2DM, type 2 diabetes. †Test
for trend. *P , 0.05 in multivariable Cox proportional hazards model.
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study is reliable.
Second, we didn’t measure fat depo-
sition by using standardized dual-energy
X-rayabsorptiometry orcomputedtomog-
raphy to evaluate association between ab-
dominal adiposity and nephropathy (22).
Instead, abdominal adiposity was esti-
mated by waist circumference, which is
suggested as a predictor of insulin resis-
tance and albuminuria (23,24). Although
we adjusted for waist circumference in all
of our multivariable survival analyses, the
HOMA-IRscoreremainedasigniﬁcantpre-
dictor of microalbuminuria development,
e i t h e ri nt h ee n t i r ec o h o r t( T a b l e2 )o r
in a subgroup of individuals with good
metabolic proﬁles (Fig. 2).
Moreover, small sample size in sub-
groups in quartiles 1–4o fg l y c e m i cc o n -
trol or blood pressure control in Table 3
could affect statistical signiﬁcance. If we
classiﬁed HOMA-IR based on its tertile,
the incidence rate ratios of tertile 3 for
subgroups with HbA1c #8%, HbA1c
.8%, blood pressure #130/80 mmHg,
and blood pressure .130/80 mmHg
were all signiﬁcant as compared with
those in tertile 1. These results indicate
the dose-response effects of HOMA-IR
on microalbuminuria were robust.
In conclusion, this is the ﬁrst pro-
spective study investigating an associa-
tion between insulin resistance and
development of microalbuminuria in
type 2 diabetic patients. We reconﬁrm
that type 2 diabetic patients predisposed
to higher insulin resistance are more
likely to develop microalbuminuria. Fu-
tureresearchshouldaimatstoppingrenal
function deterioration by improving in-
sulin sensitivity for type 2 diabetes with
high insulin resistance.
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Quartile 2 22 283.6 77.5 1.55 (0.86–2.81)
Quartile 3 25 284.6 87.8 1.76 (0.99–3.13)
Quartile 4 28 293.2 95.5 1.91 (1.10–3.36)
Cumulative average BP .130/80 mmHg (n = 448)
Quartile 1 27 309.7 87.1 1.00 0.049
Quartile 2 40 458.4 87.2 1.00 (0.61–1.64)
Quartile 3 41 431.6 95.0 1.09 (0.67–1.79)
Quartile 4 41 403.7 101.6 1.16 (0.71–1.91)
BP, blood pressure; RR, rate ratio. *Test for trend for incidence rate ratio from HOMA-IR Q1 to Q4.
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